Report Overview

China Melanoma Treatment market size stood at around USD 2.95 billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of around XX% during the forecast period.

Melanoma has become one of the diseases that seriously endangers the health of the Chinese people. Due to the high mortality rate, high metastasis rate, and difficulty in treatment, melanoma is known as the "king of cancer. It accounts for 10.8% of the entire tumor market. In China melanoma drugs are the most used anti-tumor drug (paclitaxel) derived from natural plants, with a market share of as high as 40%. However, chemical drugs occupy a dominant position and have an absolute advantage.



Market Drivers

Increasing prevalence of skin allergies, melanoma, and other skin cancers is high, which serves as an opportunity for drug companies to gain a larger share in the Chinese melanoma drugs market. Increasing demand for cost-efficient therapeutics has encouraged major players to develop cheaper and effective drugs. These factors are expected to fuel the growth of the overall market in the coming years. Increase in melanoma cases, presence of effective immunotherapies acts as primary market drivers for Chinese melanoma market. Furthermore, Government initiatives aided for that growth, and Technological advancements & increasing R&D on cancer diagnosis fuelled the market.